Sino Biopharmaceutical Dirección

Dirección controles de criterios 1/4

El CEO de Sino Biopharmaceutical's es Eric S. Y. Tse , nombrado en Jul 2022, tiene una permanencia de 1.83 años. compensación anual total es CN¥49.69M, compuesta por 45.4% salario y 54.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 22.11% de las acciones de la empresa, por valor de HK$11.80B. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 9.1 años, respectivamente.

Información clave

Eric S. Y. Tse

Chief Executive Officer (CEO)

CN¥49.7m

Compensación total

Porcentaje del salario del CEO	45.4%
Permanencia del CEO	1.8yrs
Participación del CEO	22.1%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	9.1yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28

An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Jan 22

Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Dec 03

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Oct 19

Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Sep 03

These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Aug 27

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Jul 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric S. Y. Tse en comparación con los beneficios de Sino Biopharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CN¥50m	CN¥23m	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

Compensación vs. Mercado: La compensación total de Eric S. Y.($USD6.88M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD926.98K).

Compensación vs. Ingresos: La compensación de Eric S. Y. ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Eric S. Y. Tse (27 yo)

1.8yrs

Permanencia

CN¥49,691,000

Compensación

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Y. Y. Tse	Executive Chairwoman of the Board	8.9yrs	CN¥49.69m	0.033% CN¥ 17.0m
Eric S. Y. Tse	CEO & Executive Director	1.8yrs	CN¥49.69m	22.11% CN¥ 11.5b
Ping Tse	Founder & Senior Executive Vice Chairman	3.8yrs	CN¥49.53m	9.12% CN¥ 4.8b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.1yrs	CN¥43.13m	16.19% CN¥ 8.4b
Mingqin Li	Senior VP & Executive Director	no data	CN¥1.20m	sin datos
Zhoushan Tian	Executive Director	no data	CN¥1.91m	sin datos
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.95% CN¥ 1.0b
Chun Ling Li	Chief Financial Officer	1.3yrs	sin datos	sin datos
Song Jin	Vice President of Public Affairs	no data	sin datos	sin datos
Sean Chen	Chief Strategy Officer	1.3yrs	sin datos	sin datos
Orphanides George	Chief Scientific Advisor of invoX	1.3yrs	sin datos	sin datos
Chau Ling Yu	Assistant VP & Financial Controller	no data	sin datos	sin datos

1.3yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1177 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Y. Y. Tse	Executive Chairwoman of the Board	8.9yrs	CN¥49.69m	0.033% CN¥ 17.0m
Eric S. Y. Tse	CEO & Executive Director	4.6yrs	CN¥49.69m	22.11% CN¥ 11.5b
Ping Tse	Founder & Senior Executive Vice Chairman	3.8yrs	CN¥49.53m	9.12% CN¥ 4.8b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.1yrs	CN¥43.13m	16.19% CN¥ 8.4b
Mingqin Li	Senior VP & Executive Director	9.1yrs	CN¥1.20m	sin datos
Zhoushan Tian	Executive Director	9.1yrs	CN¥1.91m	sin datos
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.95% CN¥ 1.0b
Zhengfei Lu	Independent Non-Executive Director	18.5yrs	CN¥376.00k	sin datos
Dakui Li	Independent Non-Executive Director	19.7yrs	CN¥376.00k	sin datos
Lu Fu Zhang	Independent Non-Executive Director	9.1yrs	CN¥376.00k	sin datos
Hong Lu	Independent Non-Executive Director	9.1yrs	CN¥342.00k	sin datos
Kwok Tung Li	Independent Non-Executive Director	3.4yrs	CN¥376.00k	0.00039% CN¥ 203.1k

9.1yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1177 se considera experimentada (9 años de antigüedad promedio).

Sino Biopharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Key Executive recently bought HK$34m worth of stock

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Less than half of directors are independent

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Recent updates

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Investor sentiment improves as stock rises 18%

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Consensus revenue estimates fall by 13%

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Upcoming dividend of HK$0.06 per share

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Upcoming dividend of HK$0.04 per share

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial